Postnatal steroids in extremely low birth weight infants: Betamethasone or hydrocortisone?

Acta Paediatrica, International Journal of Paediatrics

Volumn 102, Issue 7, 2013, Pages 689-694

  Ben Said, Mohamed ^a,b   Hays, Stéphane ^a,c   Loys, Claire Marie ^a,d   Coletto, Ludivine ^a,d   Godbert, Isabelle ^a   Picaud, Jean Charles ^a,c,d  

^a CROIX ROUSSE HOSPITAL   (France)

^b UNIVERSITY OF TUNIS   (Tunisia)

^c Human Nutrition Research Center   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Extubation; Growth; Hyperglycaemia; Prematurity; Steroid

Indexed keywords

BETAMETHASONE; GLUCOSE; HYDROCORTISONE SODIUM SUCCINATE;

ARTICLE; BLOOD PRESSURE MONITORING; CALORIC INTAKE; CHILD GROWTH; COMPARATIVE EFFECTIVENESS; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG TOLERANCE; EXTREMELY LOW BIRTH WEIGHT; EXTUBATION; GLUCOSE BLOOD LEVEL; HEAD CIRCUMFERENCE; HUMAN; INFANT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AIRWAY MANAGEMENT; BETAMETHASONE; BRONCHOPULMONARY DYSPLASIA; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; MALE; RETROSPECTIVE STUDIES;

EID: 84878539387     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/apa.12255     Document Type: Article

References (31)

1. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126: 443-56.
2. Jobe AJ,. The new BPD: an arrest of lung development. Pediatr Res 1999; 46: 641-3.
3. Jobe AH,. Postnatal corticosteroids for bronchopulmonary dysplasia. Clin Perinatol 2009; 36: 177-88.
4. Watterberg K,. Evidence-based neonatal pharmacotherapy: postnatal corticosteroids. Clin Perinatol 2012; 39: 47-59.
5. Jarreau PH, Fayon M, Baud O, Autret-Leca E, Danan M, de Verdelhan A, et al. The use of postnatal corticosteroid therapy in premature infants to prevent or treat bronchopulmonary dysplasia: current situation and recommendations. Arch Pediatr 2010; 17: 1480-7.
6. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004; 350: 1304-13.
7. O'Shea TM, Washburn LK, Nixon PA, Goldstein DJ,. Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age. Pediatrics 2007; 120: 594-602.
8. van der Heide-Jalving M, Kamphuis PJ, van der Laan MJ, Bakker JM, Wiegant VM, Heijnen CJ, et al. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? Acta Paediatr 2003; 92: 827-35.
9. De Castro M, El-Khoury N, Parton L, Ballabh P, LaGamma EF,. Postnatal betamethasone vs dexamethasone in premature infants with bronchopulmonary dysplasia: a pilot study. J Perinatol 2009; 29: 297-304.
10. Cambonie G, Mesnage R, Milési C, Pidoux O, Veyrac C, Picaud JC,. Betamethasone impairs cerebral blood flow velocities in very premature infants with severe chronic lung disease. J Pediatr 2008; 152: 270-5.
11. Cambonie G, Mesnage R, Milési C, Rideau A, Veyrac C, Picaud JC,. Hydrocortisone treatment for severe evolving bronchopulmonary dysplasia and cerebral haemodynamics. Arch Dis Child Fetal Neonatal Ed 2009; 94: F154-5.
12. Lodygensky GA, Rademaker K, Zimine S, Gex-Fabry M, Lieftink AF, Lazeyras F, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 2005; 116: 1-7.
13. Karemaker R, Heijnen CJ, Veen S, Baerts W, Samsom J, Visser GH, et al. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr Res 2006; 60: 745-50.
14. Rademaker KJ, Rijpert M, Uiterwaal CS, Lieftink AF, van Bel F, Grobbee DE, et al. Neonatal hydrocortisone treatment related to 1H-MRS of the hippocampus and short-term memory at school age in preterm born children. Pediatr Res 2006; 59: 309-13.
15. Needelman H, Hoskoppal A, Roberts H, Evans M, Bodensteiner JB,. The effect of hydrocortisone on neurodevelopmental outcome in premature infants less than 29 weeks' gestation. J Child Neurol 2010; 25: 448-52.
16. Rademaker KJ, de Vries LS, Uiterwaal CS, Groenendaal F, Grobbee DE, van Bel F,. Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up. Arch Dis Child Fetal Neonatal Ed 2008; 93: F58-63.
17. Rastogi A, Akintorin SM, Bez ML, Morales P, Pildes RS,. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics 1996; 98: 204-10.
18. Usher R, McLean F,. Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr 1969; 74: 901-10.
19. Watterberg KL, American Academy of Pediatrics. Committee on Fetus and Newborn. Policy statement-postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010; 126: 800-8.
20. De Kloet ER, Vreugdenhil E, Oitzl MS, Joëls M,. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998; 19: 269-301.
21. McEwen BS,. The brain is an important target of adrenal steroid actions. A comparison of synthetic and natural steroids. Ann N Y Acad Sci 1997; 823: 201-13.
22. Crochemore C, Lu J, Wu Y, Liposits Z, Sousa N, Holsboer F, et al. Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry 2005; 10: 790-8.
23. Hassan AH, Von Rosenstiel P, Patchev VK, Holsboer F, Almeida OF,. Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Exp Neurol 1996; 140: 43-52.
24. Reynolds JW, Colle E, Ulstrom RA,. Adrenocortical steroid metabolism in newborn infants. V. Physiologic disposition of exogenous cortisol loads in the early neonatal period. J Clin Endocrinol Metab 1962; 22: 245-54.
25. Watterberg KL, Cook K, Gifford KL,. Pharmacokinetics of hydrocortisone in extremely low birthweight infants in the first week of life. Pediatr Res 1996; 39: 251-251.
26. Yamasaki C, Uchiyama A, Nakanishi H, Masumoto K, Aoyagi H, Washio Y, et al. Hydrocortisone and long-term outcomes in very-low-birthweight infants. Pediatr Int 2012; 54: 465-70.
27. Rademaker KJ, Uiterwaal CS, Groenendaal F, Venema MM, van Bel F, Beek FJ, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr 2007; 150: 351-7.
28. Autret-Leca E, Bauer S, Alberti C, Jonville-Béra AP, Aujard Y, Bensouda-Grimaldi L, et al. Postnatal glucocorticoids in preterm neonates: use in French neonatal centres in 2006. Arch Dis Child Fetal Neonatal Ed 2008; 93: F398.
29. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001; 344: 95-101.
30. Horan MJ, Sinaiko AR,. Synopsis of the Report of the Second Task Force on Blood Pressure Control in Children. Hypertension 1987; 10: 115-21.
31. Flynn JT,. Neonatal hypertension: diagnosis and management. Pediatr Nephrol 2000; 14: 332-41.